Metronidazole Noridem (Metronidazole)

Metronidazole Noridem is indicated for several anaerobic and protozoal infections across different organ systems.

• Bacterial vaginosis: eradicates the anaerobic bacteria responsible, reducing symptoms and recurrence.
• Trichomoniasis: eliminates Trichomonas vaginalis, relieving infection signs.
• Anaerobic bacterial infections: provides bactericidal activity against susceptible anaerobes, aiding resolution of infection.
• Intra‑abdominal infections: treats mixed aerobic‑anaerobic infections in the peritoneal cavity.
• Pelvic inflammatory disease: targets anaerobic pathogens contributing to PID, supporting clinical improvement.
• Clostridioides difficile infection (adjunctive therapy): used alongside standard therapy to reduce toxin production.

• Metronidazole is taken up by anaerobic microorganisms and reduced by ferredoxin‑type proteins to generate nitro radical anions. These reactive intermediates interact with DNA, causing strand breakage and loss of helical structure, and also inhibit nucleic acid synthesis, leading to cell death. The selective reduction in low‑oxygen environments provides targeted activity against anaerobic bacteria and certain protozoa.

Metronidazole may cause a range of adverse reactions, most of which are dose‑related and reversible after discontinuation.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Metallic taste: transient metallic sensation in the mouth.
• Headache: mild headache episodes.
• Diarrhea: loose stools without severe dehydration.
• Skin rash: mild erythema or itching.

Serious or Rare Side Effects

• Seizures: neurologic events requiring immediate medical attention.
• Peripheral neuropathy: tingling or numbness in extremities.
• Stevens‑Johnson syndrome: severe skin blistering and mucosal involvement.
• Hepatotoxicity: elevated liver enzymes or jaundice.
• Hypersensitivity reactions: anaphylaxis or severe allergic response.

Before initiating Metronidazole Noridem, consider the following precautions to ensure safe use.

• Pregnancy: Category B, use only if benefits outweigh potential risks.
• Breastfeeding: excreted in milk; assess infant risk before continuation.
• Liver impairment: dose may need adjustment; monitor hepatic function.
• Alcohol interaction: avoid alcohol due to disulfiram‑like reaction.
• Renal dysfunction: monitor renal function, especially in prolonged therapy.
• Store at ambient temperature: keep below 25°C, protect from light and moisture in original container.

Metronidazole can interact with several medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid)

• Alcohol: causes severe flushing, tachycardia, and nausea.
• Warfarin: may increase anticoagulant effect, raising bleeding risk.
• Lithium: can raise lithium levels, leading to toxicity.
• Cytochrome P450 inducers (e.g., rifampin, carbamazepine): markedly reduce metronidazole concentrations.
• Disulfiram: additive disulfiram‑like reactions.

Moderate Interactions (Monitor Closely)

• Cimetidine: may increase metronidazole plasma levels.
• Phenytoin: may enhance neurotoxic effects.
• Oral contraceptives: possible reduction in efficacy; advise backup contraception.
• Theophylline: may increase theophylline levels, monitor for toxicity.
• Isoniazid: may increase risk of peripheral neuropathy.